In ‘new crisis era,’ Tokyo needs help from Seoul and DC. Can it count on them?Manchin, Sinema prevent Democrats from locking in majority on labor board through 2026

Among the most incredible success stories in cryptocurrency history is Shiba Inu (SHIB). Inspired by the venerable Shiba Inu dog, which symbolizes Dogecoin, SHIB started as a meme coin launched in August 2020 under the pseudonymous inventor " Ryoshi." Although many first discounted Shiba Inu as just another meme token, her quick ascent highlighted the volatility and possibilities of the crypto market. SHIB's price at first was almost zero, at $0.000000000056. One forward-looking crypto trader bought a small amount of this young currency. The token had an unheard-before boom by May 2021, rising to $0.00003791—a rise of almost 67 million percent. The trader's investment became shockingly $340 million from this fast rise. The token's momentum continued; by October 2021, SHIB had reached an all-time high of $0.000084. Celebrity sponsorships, social media buzz, and meme coin popularity spurred this boom. After its peak, though, SHIB showed notable volatility, just as many cryptocurrencies do. As of December 2024, SHIB trades at $0.000022; while still distant from its all-time high, this price reflects its ongoing impact on the crypto market. Rexas Finance (RXS): The Next Millionaire-Maker Coin Although community support and enthusiasm mostly drove SHIB's growth, Rexas Finance presents a more distinct and durable value proposition. Rexas Finance is not just another cryptocurrency; it represents a groundbreaking shift in how premium assets are tokenized and traded. Rexas Finance helps consumers fractionalize and trade assets, including real estate, fine art, and luxury products, on the blockchain by concentrating on Real World Asset (RWA) tokenization. Thanks to this democratization of access, common investors can own shares in valuable assets once solely accessible to the rich elite. Combining blockchain technology with practical, real-world use helps Rexas Finance build on the scalability and speed Solana brought forth. This creative strategy makes Rexas Finance a revolutionary change in the crowded cryptocurrency market. Rexas Finance has shown notable results already. At $0.15 right now, the RXS token is currently in the 10th phase of its presale and has sold 374,231,469 tokens, raising a total of $32,260,062. This excessive investor interest highlights growing faith in Rexas Finance's mission and long-term worth. One of the most interesting investment prospects on the market, analysts estimate the token may witness an amazing rise of up to 100,000% during the expected 2025 bull run. Another element inspiring investor excitement is Rexas Finance's entry-level pricing. At just $0.15, even small investors can invest in a project ready for exponential returns. Unlike speculative tokens, which are based on utility and practical application, Rexas offers a strong basis for long-term adoption. Rexas Finance's values are mostly security and openness. The initiative has undergone a thorough CertiK assessment to guarantee that its infrastructure is secure and its smart contracts are free from flaws. This degree of examination gives investors extra confidence when negotiating a market sometimes beset by fraud and untrustworthy projects. Rexas Finance has also obtained listings on reliable sites such as CoinGecko and CoinMarketCap. These sponsorships strengthen the project's legitimacy and raise its profile, confirming its status as a major rival in the cryptocurrency scene. Rexas Finance has gone beyond to encourage community participation and honor its early backers. One monument to this dedication is the $1,000,000 RXS Millionaire Giveaway. Twenty lucky investors will each win $50,000 worth of RXS tokens, providing a significant incentive to participate in the project’s early stages. This program emphasizes Rexas Finance's commitment to creating a devoted and involved community—a necessary component for long-term crypto success. Why Rexas Finance Could Outshine SHIB Although Shiba Inu's meteoric ascent enthralled the cryptocurrency market, market hype and speculation were primarily responsible. Rexas Finance , on the other hand, presents a sustainable strategy anchored in addressing practical issues. By closing the distance between conventional banking and blockchain technology, Rexas offers real value and creates access to unexplored industries. Rexas Finance is an exciting option for those looking for the next millionaire-maker coin. Combining its transparent operations, creative approach to RWA tokenization, strong community engagement, and entry-level cost gives this enterprise unmatched potential. All eyes will be on Rexas Finance as 2025 draws near to see whether it can match—and maybe exceed—the success of Shiba Inu. RXS offers chances for individuals who missed the SHIB wave to ride the next major wave in cryptocurrencies. For more information about Rexas Finance (RXS) visit the links below: Website: https://rexas.com Win $1 Million Giveaway: https://bit.ly/Rexas1M Whitepaper: https://rexas.com/rexas-whitepaper.pdf Twitter/X: https://x.com/rexasfinance Telegram: https://t.me/rexasfinance Join our WhatsApp Channel to get the latest news, exclusives and videos on WhatsApp _____________ Disclaimer: Analytics Insight does not provide financial advice or guidance. Also note that the cryptocurrencies mentioned/listed on the website could potentially be scams, i.e. designed to induce you to invest financial resources that may be lost forever and not be recoverable once investments are made. You are responsible for conducting your own research (DYOR) before making any investments. Read more here.Brock Purdy will miss Sunday's game for the 49ers with a shoulder injury

Northrop Grumman Announces New $3 Billion Share Repurchase AuthorizationUTRECHT, The Netherlands and CAMBRIDGE, Mass., Dec. 16, 2024 (GLOBE NEWSWIRE) -- Merus N.V . (Nasdaq: MRUS), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics ® and Triclonics ® ) for cancer, today announced that the first patient has been dosed in the Company's phase 2 trial evaluating petosemtamab monotherapy in heavily pretreated (3L+) metastatic colorectal cancer (mCRC). Petosemtamab is a Biclonics ® targeting EGFR and LGR5. The phase 2, open-label trial will evaluate the safety and antitumor activity of petosemtamab monotherapy in 3L+ mCRC, post anti-EGFR therapy. To be eligible for enrollment, patients must lack certain mutations as detected in plasma by ctDNA NGS, including KRAS, NRAS. "We discovered petosemtamab from an unbiased screen of over 500 bispecific antibodies tested for the ability to inhibit cancer-derived, as compared to matched normal tissue derived, organoids. In preclinical CRC models, petosemtamab consistently demonstrates superior activity compared to cetuximab, a mainstay therapy in mCRC,” said John de Kruif Ph.D., Chief Technology Officer at Merus. "I am hopeful our unique platform technologies will translate into improved therapies for patients with heavily pretreated mCRC.” About Petosemtamab Petosemtamab, or MCLA-158, is a Biclonics ® low-fucose human full-length IgG1 antibody targeting the epidermal growth factor receptor (EGFR) and the leucine-rich repeat containing G-protein-coupled receptor 5 (LGR5). Petosemtamab is designed to exhibit three independent mechanisms of action including inhibition of EGFR-dependent signaling, LGR5 binding leading to EGFR internalization and degradation in cancer cells, and enhanced antibody-dependent cell-mediated cytotoxicity (ADCC) and antibody-dependent cellular phagocytosis (ADCP) activity. About Merus N.V. Merus is a clinical-stage oncology company developing innovative full-length human bispecific and trispecific antibody therapeutics, referred to as Multiclonics ® . Multiclonics ® are manufactured using industry standard processes and have been observed in preclinical and clinical studies to have several of the same features of conventional human monoclonal antibodies, such as long half-life and low immunogenicity. For additional information, please visit Merus' website and LinkedIn . Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including without limitation, statements regarding the evaluation of petosemtamab in patients with mCRC, the clinical study design and objectives of the phase 2 study; and the hope that our unique platform technologies will translate into improved therapies for patients with heavily pretreated mCRC. These forward-looking statements are based on management's current expectations. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to, the following: our need for additional funding, which may not be available and which may require us to restrict our operations or require us to relinquish rights to our technologies or antibody candidates; potential delays in regulatory approval, which would impact our ability to commercialize our product candidates and affect our ability to generate revenue; the lengthy and expensive process of clinical drug development, which has an uncertain outcome; the unpredictable nature of our early stage development efforts for marketable drugs; potential delays in enrollment of patients, which could affect the receipt of necessary regulatory approvals; our reliance on third parties to conduct our clinical trials and the potential for those third parties to not perform satisfactorily; impacts of the volatility in the global economy, including global instability, including the ongoing conflicts in Europe and the Middle East; we may not identify suitable Biclonics ® or bispecific antibody candidates under our collaborations or our collaborators may fail to perform adequately under our collaborations; our reliance on third parties to manufacture our product candidates, which may delay, prevent or impair our development and commercialization efforts; protection of our proprietary technology; our patents may be found invalid, unenforceable, circumvented by competitors and our patent applications may be found not to comply with the rules and regulations of patentability; we may fail to prevail in potential lawsuits for infringement of third-party intellectual property; and our registered or unregistered trademarks or trade names may be challenged, infringed, circumvented or declared generic or determined to be infringing on other marks. These and other important factors discussed under the caption "Risk Factors” in our Quarterly Report on Form 10-Q for the period ended September 30, 2024, filed with the Securities and Exchange Commission, or SEC, on October 31, 2024, and our other reports filed with the SEC, could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. Any such forward-looking statements represent management's estimates as of the date of this press release. While we may elect to update such forward-looking statements at some point in the future, we disclaim any obligation to do so, even if subsequent events cause our views to change, except as required under applicable law. These forward-looking statements should not be relied upon as representing our views as of any date subsequent to the date of this press release. Multiclonics ® , Biclonics ® and Triclonics ® are registered trademarks of Merus N.V. CONTACT: Investor and Media Inquiries: Sherri Spear Merus N.V. SVP Investor Relations and Strategic Communications 617-821-3246 [email protected] Kathleen Farren Merus N.V. Assoc. Director IR/Corp Comms 617-230-4165 [email protected]

Eugene Boakye Antwi Reflects on NPP’s 2024 Defeat and the Lessons Learned